© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
October 04, 2017
Article
Complete phase 3 data show that a biosimilar almost beat reference trastuzumab (Herceptin) for the primary endpoint of pathologic complete response in patients with HER2-positive early breast cancer.